Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H25NO |
Molecular Weight | 259.3865 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H]1CCCC[C@H]1N2CCC(CC2)C3=CC=CC=C3
InChI
InChIKey=YSSBJODGIYRAMI-IAGOWNOFSA-N
InChI=1S/C17H25NO/c19-17-9-5-4-8-16(17)18-12-10-15(11-13-18)14-6-2-1-3-7-14/h1-3,6-7,15-17,19H,4-5,8-13H2/t16-,17-/m1/s1
Molecular Formula | C17H25NO |
Molecular Weight | 259.3865 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Vesamicol is an experimental drug, acting presynaptically by inhibiting acetylcholine (ACh) uptake into synaptic vesicles and reducing its release. Vesamicol (2-[4-phenylpiperidino] cyclohexanol) inhibits the transport of acetylcholine into synaptic vesicles in cholinergic nerve terminals. In addition to its effects on vesicular acetylcholine transport, vesamicol also possesses some sodium channel and alpha-adrenoceptor blocking activity. Vesamicol represents a unique tool for investigating presynaptic mechanisms in cholinergic nerve terminals. Vesamicol induced potent apoptosis of human BACs in cell culture and nude mice models. Vesamicol did not have any effect on EGF or insulin-like growth factor-II-induced growth of human bronchioalveolar carcinomas (BACs). siRNA-mediated attenuation of VAChT reversed the apoptotic activity of vesamicol. Vesamicol inhibited Akt phosphorylation during cell death and that overexpression of constitutively active Akt reversed the apoptotic activity of vesamicol. Disruption of nicotine-induced cholinergic signaling by agents such as vesamicol may have applications in BAC therapy.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26138195 | https://www.ncbi.nlm.nih.gov/pubmed/26872437 | https://www.ncbi.nlm.nih.gov/pubmed/24687885https://www.ncbi.nlm.nih.gov/pubmed/8619013 | https://www.ncbi.nlm.nih.gov/pubmed/9205789 | https://www.ncbi.nlm.nih.gov/pubmed/1925971
Curator's Comment: CNS active in animals
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
2.1 nM [Kd] | |||
Target ID: CHEMBL4767 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7702637 |
2.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Demonstration of a receptor in Torpedo synaptic vesicles for the acetylcholine storage blocker L-trans-2-(4-phenyl[3,4-3H]-piperidino) cyclohexanol. | 1986 Apr |
|
A further study of the neuromuscular effects of vesamicol (AH5183) and of its enantiomer specificity. | 1988 Apr |
|
The effects of l-vesamicol on transmitter release from rat motor nerve terminals at high frequencies of nerve stimulation. | 1989 Dec |
|
The effects of L-vesamicol, an inhibitor of vesicular acetylcholine uptake, on two populations of miniature endplate currents at the snake neuromuscular junction. | 1990 |
|
Synthesis and evaluation of radiolabeled piperazine derivatives of vesamicol as SPECT agents for cholinergic neurons. | 2001 Apr |
|
Analysis of uptake and release of newly synthesized acetylcholine in PC12 cells overexpressing the rat vesicular acetylcholine transporter (VAChT). | 2002 Apr 30 |
|
PET and SPET tracers for mapping the cardiac nervous system. | 2002 Mar |
|
Ethanol elevates accumbal dopamine levels via indirect activation of ventral tegmental nicotinic acetylcholine receptors. | 2003 Apr 25 |
|
Structural changes of benzylether derivatives of vesamicol and their influence on the binding selectivity to the vesicular acetylcholine transporter. | 2005 Dec |
|
Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. | 2005 Feb 1 |
|
Mutational and pH analysis of ionic residues in transmembrane domains of vesicular acetylcholine transporter. | 2005 Jun 7 |
|
Vesicles in snake motor terminals comprise one functional pool and utilize a single recycling strategy at all stimulus frequencies. | 2005 Oct 15 |
|
New transport assay demonstrates vesicular acetylcholine transporter has many alternative substrates. | 2005 Sep |
|
Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor. | 2006 Apr 15 |
|
Release of acetylcholine by Hon-Chi to raise insulin secretion in Wistar rats. | 2006 Aug 14 |
|
Release of acetylcholine to raise insulin secretion in Wistar rats by oleanolic acid, one of the active principles contained in Cornus officinalis. | 2006 Aug 14 |
|
Increase of insulin secretion by ginsenoside Rh2 to lower plasma glucose in Wistar rats. | 2006 Jan-Feb |
|
Evaluation of (+)-p-[11C]methylvesamicol for mapping sigma1 receptors: a comparison with [11C]SA4503. | 2006 May |
|
Mutational and bioinformatics analysis of proline- and glycine-rich motifs in vesicular acetylcholine transporter. | 2006 Sep |
|
The potential of (-)-o-[11C]methylvesamicol for diagnosing cholinergic deficit dementia. | 2009 Feb |
|
Neuroimaging of the vesicular acetylcholine transporter by a novel 4-[18F]fluoro-benzoyl derivative of 7-hydroxy-6-(4-phenyl-piperidin-1-yl)-octahydro-benzo[1,4]oxazines. | 2009 Jan |
|
Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapy. | 2009 Nov |
|
Multiple protonation states of vesicular acetylcholine transporter detected by binding of [3H]vesamicol. | 2009 Sep 29 |
|
Equilibrium binding and transport by vesicular acetylcholine transporter. | 2010 |
|
Possible important pair of acidic residues in vesicular acetylcholine transporter. | 2010 Apr 13 |
|
Synthesis and in vitro biological evaluation of carbonyl group-containing inhibitors of vesicular acetylcholine transporter. | 2010 Apr 8 |
|
Enantioseparation of vesamicol and novel vesamicol analogs by high-performance liquid chromatography on different chiral stationary phases. | 2010 Jun 11 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26872437
Curator's Comment: I.p route in rats was used: to assess the effect of vesamicol in vivo, we examined cholinergic parameters, such as the subcellular distribution of ACh, activities of enzymes, uptake of choline, and muscarinic receptor binding in the striatum, hippocampus, and cerebral cortex of rats 30 and 60 min after intraperitoneal injection of vesamicol (3 mg/kg) or of vesamicol in combination with DDVP (5 mg/kg), which was administered 10 min before vasamicol.
https://www.ncbi.nlm.nih.gov/pubmed/9205789
Nonhuman primates: Occupancy studies found that ~0.0057 mg/kg of (-)-vesamicol produced 50% VAChT occupancy in the striatum.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1375854
1. The effects of vesamicol, an inhibitor of vesicular acetylcholine (ACh) storage, were studied on trains of endplate currents (e.p.cs) in the cut rat hemidiaphragm nerve-muscle preparation and on trains of focally recorded nerve terminal current waveforms in the mouse triangularis sterni nerve-muscle preparation. 2. In the rat, 0.1 and 1 microM (-)-vesamicol produced an enhancement of the rundown of e.p.c. amplitudes during trains of high frequency (50 Hz) nerve stimulation. However, 1 microM (+)-vesamicol had no effect on the rundown of e.p.c. amplitudes. 3. In the mouse, high concentrations of (-)-vesamicol (10-100 microM) produced a concentration- and stimulation-dependent decrease in the amplitude of the second negative-going deflection of focally recorded nerve terminal current waveforms. 4. At 1 mM, (-)-vesamicol produced a stimulation-independent decrease in the amplitude of the first negative-going deflection of the nerve terminal current waveforms, an increase in signal delay and evidence of nerve conduction failure. These all indicate a local anaesthetic-like block of nodal Na(+)-channels. 5. In contrast to its effects on trains of e.p.cs, the effects of vesamicol on the nerve terminal current waveforms were not stereoselective, the (+)-isomer being equipotent with the (-)-isomer. 6. Low concentrations of the Na(+)-channel blocking toxin, tetrodotoxin (15-60 nM), produced similar changes in the focally recorded nerve terminal current waveforms to those seen with vesamicol. 7. It is concluded that the stereoselective rundown of e.p.c. amplitudes produced by (-)-vesamicol is due to an effect, either direct or indirect, on ACh mobilization within motor nerve terminals. Furthermore, in mammalian species, the inhibitory effects of vesamicol on nodal Na+-channels which are seen at high concentrations do not contribute to the principal neuromuscular effects of the compound.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:55:45 GMT 2023
by
admin
on
Sat Dec 16 09:55:45 GMT 2023
|
Record UNII |
3D416V0FLM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3D416V0FLM
Created by
admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
|
PRIMARY | |||
|
300000002058
Created by
admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
|
PRIMARY | |||
|
22232-64-0
Created by
admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
659840
Created by
admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
|
PRIMARY | |||
|
Vesamicol
Created by
admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
|
PRIMARY | |||
|
115362-28-2
Created by
admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
|
PRIMARY | |||
|
DTXSID701009898
Created by
admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ACTIVE ENANTIOMER->RACEMATE |